ERT Announces Availability of Site Selection Analytics for Insights Cloud™
Philadelphia (PRWEB) June 11, 2015 -- ERT, a leading global provider of high-quality patient safety and efficacy endpoint data collection, cloud analytics and workflow solutions, today announced the addition of Site Selection Analytics within the ERT Insights Cloud. Site Selection Analytics joins the Insights Cloud™ suite of data analytics, visualization and workflow applications that examine real-time clinical data and deliver actionable insights and process optimization to pharmaceutical companies and Clinical Research Organizations (CROs).
ERT’s Site Selection Analytics is available to deliver data on over 40,000 sites and millions of trial endpoints to provide sponsors and CROs with an industry-unique set of data to complement their investigational site evaluation process. Through an intuitive cloud-based interface, users can set search criteria based on geographic location, therapeutic area, indication, study phase, patient population and site activity– and then filter data over configurable periods of time to evaluate relative performance on certain behavioral and performance criteria set by ERT. Reports are generated based on filtered criteria to deliver targeted site analysis, assisting sponsors and CROs to identify sites for inclusion in clinical trials. With site inefficiencies responsible for an estimated 45% of study delays, ERT’s Site Selection Analytics provides critical insights for assessing sites’ relative performance on collecting data endpoints.
“ERT’s Site Selection Analytics offers exclusive quality data metrics on millions of ECGs, spirometry and electronic Clinical Outcome Assessment (eCOA) data endpoints,” says Amy Furlong, Executive Vice President, Cardiac Safety and eClinical Insights Solutions, ERT, “While there is a great deal of information in the public domain on patient enrollment trends, ERT’s Site Selection Analytics is uniquely situated to supplement these data points with real-time indicators of site performance based on the quality of collected endpoints.”
Site Selection is the latest addition to the ERT Insights Cloud, a first-in-class solution that is changing the paradigm of clinical trials software by offering technology-agnostic integration and automated data harmonization through its cloud-based data hub, EXPERT® Central. This software as a service (SaaS) offering coalesces enterprise-wide data sources and applies configurable analytical algorithms to gain unique insights on actionable risk and relative performance trends.
“With Site Selection Analytics, ERT is continuing to build on its vision for Insights Cloud, empowering our customers with real-time actionable insight,” continued Furlong. “With over 40 years of experience working with investigator sites, collecting millions of endpoints and delivering high quality endpoint data, ERT is uniquely positioned to deliver the business analytics our customers need to gain operational efficiencies so they can dramatically reduce trial costs and improve the quality of their clinical trials.”
ERT will demonstrate Site Selection Analytics and many other original products at its Innovation Lab Booth #2000 and also at the expanded ERT Booth #2025 during the Drug Information Association (DIA) Annual Meeting in Washington, DC beginning June 15, 2015. For more information, visit http://www.ert.com/dia-annual-meeting.
Additional information about Site Selection Analytics and other ERT innovative clinical trial tools is available at http://www.ert.com/insights-cloud/analytics.
About ERT
ERT (http://www.ert.com) is a leading provider of high-quality patient safety and efficacy endpoint data collection solutions for use in clinical drug development. ERT delivers a combination of technology, services and clinical consulting that increase the accuracy and reliability of patient data and improve the efficiency of the clinical development process throughout the product lifecycle. ERT delivers the most widely deployed solutions in centralized Cardiac Safety, Respiratory, Suicide Risk Assessment, electronic Clinical Outcome Assessments (eCOA) – which includes patient-, clinician-, observer- and performance-reported outcomes – and cloud- based analytics and performance metrics. By efficiently integrating these solutions through a system built upon a scientific and regulatory foundation, ERT collects, analyzes and delivers safety and efficacy data critical to the approval, labeling and reimbursement of pharmaceutical products. ERT is a global organization with headquarters in Philadelphia, PA and offices throughout the U.S., U.K., Switzerland, Japan and Germany.
Christine Tobin, ERT, http://www.ert.com/, +1 (412) 719-4568, [email protected]
Share this article